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Short running head: Pancreatic surgery during COVID-19 pandemic 
 
 
MINI-ABSTRACT  
This global survey among members of seven international pancreatic associations and study 
groups elucidates the role of pancreatic surgery during the COVID-19 pandemic, regarding 
patient selection for the surgical and oncological treatment of pancreatic diseases to support 
clinical decision-making and creating a starting point for further discussion. 
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STRUCTURED ABSTRACT  
Objective: To clarify the role of pancreatic surgery during the COVID-19 pandemic to 
optimize patients’ and clinicians’ safety and safeguard health care capacity.  
Summary Background Data: The COVID-19 pandemic heavily impacts health care systems 
worldwide. Cancer patients appear to have an increased risk for adverse events when infected 
by COVID-19, but the inability to receive oncological care seems may be an even larger 
threat, particularly in case of pancreatic cancer.  
Methods: An online survey was submitted to all members of seven international pancreatic 
associations and study groups, investigating the impact of the COVID-19 pandemic on 
pancreatic surgery using 21 statements (April, 2020). Consensus was defined as >80% 
agreement among respondents and moderate agreement as 60-80% agreement. 
Results: A total of 337 respondents from 267 centers and 37 countries spanning five 
continents completed the survey. Most respondents were surgeons (n = 302, 89.6%) and 
working in an academic center (n = 286, 84.9%). The majority of centers (n = 166, 62.2%) 
performed less pancreatic surgery because of the COVID-19 pandemic, reducing the weekly 
pancreatic resection rate from 3 (IQR 2-5) to 1 (IQR 0-2) (P < 0.001). Most centers screened 
for COVID-19 prior to pancreatic surgery (n = 233, 87.3%). Consensus was reached on 13 
statements and five statements achieved moderate agreement.  
Conclusions: This global survey elucidates the role of pancreatic surgery during the COVID-
19 pandemic, regarding patient selection for the surgical and oncological treatment of 
pancreatic diseases to support clinical decision-making and creating a starting point for 
further discussion.  
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INTRODUCTION 
The World Health Organization (WHO) declared a pandemic of coronavirus disease 
(COVID-19) (SARS-CoV-2) on March 11, 2020.
1 
The rapid spread of COVID-19 infections 
heavily impacts health care systems worldwide, resulting in limitations in both hospital and 
intensive care unit (ICU) capacity.
2 
As a result, this pandemic not only affects COVID-19 
patients, but strikes the entire health care system including the care for patients with 
pancreatic cancer and other pancreatic diseases.
3  
Recent large series suggest an increased risk for cancer patients to develop severe 
complications when infected by COVID-19, including those who were treated with surgery 
or chemotherapy in the last month.
4
 Pursuing oncological care exposes both health care 
professionals and vulnerable patients to become infected by COVID-19. However, the 
inability to receive medical and/or surgical care seems to be an equal threat for cancer 
patients as well.
5
 The highly aggressive biology of pancreatic cancer requires the 
continuation of oncological care during the COVID-19 pandemic,
6,7
 but an unambiguous 
strategy is needed to support health care professionals in clinical decision-making.  
Therefore, this international survey study aimed to clarify the role of pancreatic surgery 
during the COVID-19 pandemic through 21 statements, aiming to optimize safety for patients 
and clinicians, and safeguard health care. 
METHODS  
Survey  
An online survey was designed and submitted to all members of seven international 
pancreatic associations and study groups: the Pancreas Club, European Pancreatic Club, 
Chinese Pancreatic Surgery Association, European Consortium on Minimally Invasive 
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Pancreatic Surgery, Study Group of Preoperative Therapy for Pancreatic Cancer, Study 
Group of Pancreatic Ductal Adenocarcinoma with Peritoneal Metastasis, and International 
Study Group on Cystic Tumors of the Pancreas using Google Forms (Google LLC, Menlo 
Park California, USA). Both surgeons and non-surgeons (e.g. gastroenterologists and medical 
oncologists) were asked to participate in this survey to balance the discussion.  
The survey consisted of 36 questions on baseline characteristics, the local impact of the 
COVID-19 pandemic on pancreatic surgery (i.e. number of pancreatic resections, triage, and 
screening), and 21 statements about the role of pancreatic surgery in the current era of the 
COVID-19 pandemic. Each statement had to be appraised using three options: agree, 
disagree, and uncertain. See Text – Supplemental Digital Content 1, 
http://links.lww.com/SLA/C199 for the survey. 
The survey was conducted in the first two weeks of April 2020. Non-respondents were 
reminded twice, because of the rapid developments in the current COVID-19 crisis and need 
for novel policy development a relatively short time window was used. Respondents were 
asked to register their name and institution to prevent overlap of members between the above-
mentioned associations. The response rate could not be calculated since associations 
submitted the survey themselves. All study procedures were reviewed and approved by the 
Colorado Multiple Institutional Review Board (COMIRB) (protocol #20-0843) at the 
University of Colorado. 
Definitions 
Pancreatic ductal adenocarcinoma, bile duct cancer, duodenal and ampullary 
adenocarcinomas, intraductal papillary mucinous neoplasms (IPMNs) and pancreatic 
neuroendocrine tumors (pNETs) were defined in accordance to the WHO definitions.
8,9
 A 
hospital was defined as a high-volume pancreatic center when performing ≥20 
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pancreatoduodenectomies annually.
10
 Consensus was defined as >80% agreement among 
respondents and moderate agreement was defined as 60-80% agreement among them. 
Statistical analysis  
Variables were processed and analyzed using IBM SPSS Statistics for Microsoft Windows 
version 26 (IBM Corp., Orchard Road Armonk, New York, US). Data were reported as 
number with percentage or as median with interquartile range (IQR). The weekly volume of 
pancreatic resections before and during the COVID-19 pandemic were compared, using the 
Wilcoxon signed-rank test for non-normally distributed variables. Sensitivity analyses were 
performed to investigate the influence of specialty, the type of center, and continent. 
Statistical significance was considered as two-tailed P-value < 0.050. 
 
RESULTS  
Participants 
A total of 337 respondents from 267 centers and 37 countries spanning five continents 
completed the online survey. See Figure 1 for the number of responses per country. Most 
respondents were working in an academic center (n = 286, 84.9%) and the majority of 
participants were surgeons (n = 302, 89.6%). See Table 1 for the characteristics of the 
respondents. The median annual hospital and individual surgeon volume of pancreatic 
resections were 75 (IQR 46-140) and 35 (IQR 20-60), respectively. 
Impact of COVID-19 pandemic  
During the peak of the COVID-19 pandemic, 67.8% (n = 181) of centers prioritized between 
different types of pancreatic resections. Prior to pancreatic surgery, most centers screened 
patients for COVID-19 (n = 233, 87.3%), whereas some centers did not (n = 31, 11.6%). See 
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Table 2 for the preoperative COVID-19 screening strategy. The majority of centers (n = 166, 
62.2%) performed less pancreatic surgery as consequence of the COVID-19 pandemic. From 
these centers, the weekly numbers of pancreatic resections decreased from 3 (IQR 2-5) to 1 
(IQR 0-2) (P < 0.001). In addition, 30.7% (n = 51) of responding centers performed no 
pancreatic surgery at all.  
Statements  
Consensus was reached on 13 from the 21 statements (62%) and moderate agreement was 
achieved on five (24%) statements. The remaining three statements had an agreement <60%. 
See Table 3-5 for the statement outcomes.  
Sensitivity analyses 
The statement outcomes barely changed after excluding the non-academic centers, without 
any shifts in the three categories of agreement. Exclusion of non-surgeons lead to the 
movement of statement 5 – regarding the prioritization of patients with limited/without 
comorbidity for surgery to increase the ICU capacity – to the lowest group of agreement 
(61.1% to 59.9%).  
Analyzing the outcomes of Europe (n = 149, 44.2%), Asia (n = 115, 34.1%) and the 
Americas (i.e. North and South America) (n = 71, 21.1%) separately demonstrated some 
changes in agreement. The European respondents did not reach consensus on statement 3 
(76.5% agreement) regarding the prioritization of patients based on objective prognostic 
factors and comorbidity. In contrast to the overall outcomes, Asia achieved consensus on 
statement 4 (81.7% agreement) to prioritize each patient for pancreatic surgery, based on 
prognostic factors. Whereas Europe agreed on the importance of high-volume centers to 
operate high-risk patients during the COVID-19 pandemic (87.9% agreement), both Asia 
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(75.7% agreement) and the Americas (76.1% agreement) did not reach consensus on 
statement 16. The recommendation for preoperative screening on COVID-19 (statement 19) 
reached solely consensus (84.5% agreement) in the Americas. See Table – Supplemental 
Digital Content 2-4, http://links.lww.com/SLA/C200, http://links.lww.com/SLA/C201, 
http://links.lww.com/SLA/C202 for the statement outcomes of Europe, Asia and the 
Americas separately.  
DISCUSSION  
This global survey study aimed to clarify the role of pancreatic surgery during the COVID-19 
pandemic through 21 statements. The statements regarding patient selection for the 
oncological and surgical treatment of pancreatic diseases could assist clinicians in their 
clinical decision-making and create a starting point for further discussion.  
A literature review was performed (see Table – Supplemental Digital Content 5, 
http://links.lww.com/SLA/C203 for the search strategy) to evaluate the current evidence 
about pancreatic surgery during the COVID-19 pandemic. Kutikov et al. concluded that 
(suspected) pancreatic cancer does not allow any treatment delay and, therefore, requires 
immediate surgical treatment, but did not address (neo)adjuvant therapy.
6
 Patients with both 
COVID-19 and cancer or treated with chemotherapy / surgery in the last months seem to be 
at risk for severe events (i.e. ICU admission requiring invasive ventilation, or death) in 
comparison to COVID-19 patients without cancer, according to a Chinese series.
4
 Therefore, 
Liang et al. advised to postpone adjuvant chemotherapy or elective surgery for stable cancer 
in endemic areas.
4
 In contrast, Ueda et al. emphasized that adjuvant therapy with curative 
intent for solid tumors should proceed, and surgery needs prioritization as well.
7
 This latter 
statement is supported by the Society of Surgical Oncology (SSO), stating that hepato-
pancreato-biliary malignancies are typically aggressive and, therefore, should not be 
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considered as ‘elective’ care. 11 In addition, the Society of American Gastrointestinal and 
Endoscopic Surgeons (SAGES) and the European Association of Endoscopic Surgery 
(EAES) recommended to postpone all elective surgery with exception of surgical care for life 
threatening diseases such as progressive malignancies.
12
 Nevertheless, the limited evidence 
regarding the role of pancreatic surgery in the era of the COVID-19 pandemic, underlines the 
need for an international survey with clear statements, aiming to guide clinicians in their 
clinical decision-making. The statement outcomes of the present international expert survey 
revealed several consensus statements as well as statements that need further discussion.  
Triage  
Patients with increased risk for postoperative respiratory failure should not be prioritized for 
surgery in absence of full hospital capacity, according to consensus statement 6. In contrast, 
only 61% agreement was reached on statement 5 comprising the proposition for surgery only 
for patients with limited/without comorbidity to minimize the use of ICU capacity for 
COVID-19 patients. The American College of Surgeons (ACS) underlined consensus 
statement 6, stating that ‘‘For elective cases with a high likelihood of postoperative ICU or 
respirator utilization, it will be more imperative that the risk of delay to the individual patient 
is balanced against the imminent availability of these resources for patients with COVID-
19’’.13 The aggressive biology of pancreatic cancer justifies elective pancreatic surgery as 
indispensable care
12
 and, therefore, should not be exclusively performed for very low risk 
patients as prevention to overload hospital resources (see the section ‘Pancreatic cancer’ 
below for further explanation and recommendations). This could be the rationale for a low 
agreement on statement 5. The ACS emphasized that continuation of ‘elective’ surgical care 
have to be frequently evaluated and adapted if needed, based on the impact of the COVID-19 
pandemic on local resources.
13
 A reliable and objective model is needed to stratify patients 
and guide prioritization in accordance to hospital capabilities, such as the recently developed 
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respiratory failure risk score (RFRS) for elective abdominal and vascular surgery, that 
identified pancreatic surgery among others as an independent risk factor for postoperative 
respiratory failure.
14
 
Screening and Protection for COVID-19  
Prior to pancreatic surgery, most centers represented in this survey screened their patients for 
symptoms of COVID-19. No consensus was reached to recommend COVID-19 preoperative 
testing/screening (statement 19). This seems a plea to obligate some type of screening, but 
not necessarily with PCR and/or CT chest, particularly considering SAGES. SAGES 
underlines the recommendation of the Corona Virus Global Surgical Collaborative (CVGSC) 
to perform some type of screening test for all patients (even if asymptomatic and without risk 
factors) who will undergo a surgical or interventional endoscopic procedure in institutions 
seeing high volumes of COVID-19 patients.
12
 In addition, ACS advised to wait for the results 
of COVID-19 testing in patients who may be infected.
13
  
Based on consensus, patients who will undergo pancreatic surgery should be informed about 
the following additional risks: COVID-19 infection during hospitalization, possible non-
optimal postoperative management (i.e. shortage of ICU beds), increased risk of COVID-19 
related mortality due to surgery or the cancer condition (statement 17). Furthermore, this 
survey convincingly recommends that operating room (OR) personnel have to wear adequate 
protective features during surgery, considering their increased risk for COVID-19 infection 
during surgical procedures (statement 20).
15,16
 
Pancreatic cancer 
According to the consensus statements for patients with pancreatic cancer, each patient 
should be operated after completing neoadjuvant therapy (statement 1), as is also advised by 
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the SSO.
11
 However, patients should be prioritized based on objective prognostic factors and 
comorbidities in case of limited resources. If surgery is postponed, patients should continue 
with neoadjuvant therapy (statement 3), but neoadjuvant therapy should not be used to select 
each patient with non-metastatic pancreatic cancer for surgery (statement 2). Subsequently, 
patients with postponed surgery need to be evaluated as soon as possible for surgery when 
resources are available again (statement 7). Oba et al. recently described the value of a new 
nomogram for pancreatic cancer, estimating patients’ predicted survival based on 
preoperative factors and confirmed the prognostic power of known predictive factors.
17
 These 
models could be used for prioritization of surgery for pancreatic cancer in case of limited 
resources. However, no consensus was reached on statement 4 and 5 to prioritize each 
pancreatic cancer patient on comorbidity and objective pancreas cancer-related prognostic 
factors, considering the life threatening nature of pancreatic cancer. Nevertheless, statement 
18 – prioritization of COVID-19 patients with a better prognosis over pancreatic cancer 
patients adhering to the process of triage for hospital resources and ICU beds – did not reach 
60% agreement. On the other hand, the difficulty to prioritize between patients with severe 
COVID-19 or resectable pancreatic cancer is conceivable. See the section ‘Triage’ for further 
explanation and recommendations.  
Italy has demonstrated the feasibility of continuing crucial cancer care during the COVID-19 
pandemic, among others by appropriate resource allocation and separate health care pathways 
between COVID-19 patients and non-infected cancer patients, structured by performance 
criteria (e.g. hospital volume).
3,18
 
Periampullary malignancies (without pancreatic cancer) 
Statement 8 proposed to manage distal bile duct cancer as equivalent to pancreatic cancer. 
However, the lack of consensus (71%) implies that surgery might have slightly less priority 
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in comparison to pancreatic cancer since 23% of respondents disagreed on the other hand. 
The SSO stated that extrahepatic bile duct cancer and ampullary and duodenal 
adenocarcinomas should be operated as soon as feasible, regardless of the presence of 
symptoms.
11
 However, a high disagreement rate (40%) was reached on statement 15 for 
postponing surgery or giving neoadjuvant chemotherapy for duodenal and ampullary cancers 
in absence of life threatening risks (i.e. bleeding, bowel obstruction). Since evidence is 
limited about the efficacy of neoadjuvant chemotherapy for these cancers so far and could not 
be deemed to stable diseases,
11 
many physicians might thought these should be resected as 
indicated.  
Benign or premalignant pancreatic diseases 
Consensus was reached to postpone surgery for benign and premalignant pancreatic diseases, 
including IPMNs, pNETs, chronic pancreatitis, and infected pancreatic necrosis. Exceptions 
comprise life threatening complications of chronic pancreatitis or infected pancreatic 
necrosis, symptomatic pNETs without effective alternative treatment options, or pNETs or 
IPMNs with suspicion for malignancy (statements 9-14).  
High-volume care 
Volume-outcome relationships in pancreatic surgery are well established with shorter hospital 
stay and lower mortality in high-volume centers.
10,19,20
 Pancreatic surgery in high-risk 
patients should not be performed in low-volume centers during the COVID-19 pandemic, 
aiming to reduce the risk of long hospital stay and major complications requiring ICU care 
(statement 16). Remarkably, the sensitivity analysis revealed that only Europe reached 
consensus in contrast to Asia and the Americas.  
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Minimally invasive surgery 
Statement 21 demonstrated the limited evidence regarding the safety of minimally invasive 
surgery, illustrated by the substantial percentage of respondents who agreed (65%) or were 
uncertain (24%). Although previous research has shown that laparoscopy can lead to 
aerosolization of blood borne viruses,
21,16,15
 SAGES advised to continue to perform 
minimally invasive surgery in accordance to their risk reducing procedural advice. SAGES 
will monitor emerging evidence considering the limited evidence about the relative risk of 
COVID-19 spreading in the OR by minimally invasive surgery in comparison to conventional 
open surgery.
12
 The ACS mentioned that aerosol-generating procedures increase the risk for 
OR personnel and may not be avoidable, but confirmed the insufficiency of evidence to 
recommend or discommend minimally invasive surgery.
13
 Meanwhile, SAGES underlined 
the proven benefits of minimally invasive surgery to reduce postoperative morbidity and 
hospital stay and, therefore, should be strongly considered in these patients.  
Strengths and limitations  
The strength of this survey is the global range of respondents, representing a wide range of 
countries and continents. However, the results should be interpreted in light of some 
limitations. First, only 10.4% non-surgeons (e.g. medical oncologists and gastroenterologists) 
participated in this survey, which could possibly outbalance the discussion regarding the 
oncological treatment of pancreatic diseases. Second, a relatively small group of eight 
countries was responsible for the majority of survey participants (76.6%). Third, only a 
minority of participants represented the non-academic centers.  
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CONCLUSION 
In summary, this survey reached consensus on the majority of statements for the role of 
pancreatic surgery during the COVID-19 pandemic to optimize safety for patients and 
clinicians and safeguard health care capacity by prioritizing only the most relevant care for 
patients with non-COVID-19 pancreatic diseases.  
The statements maybe be updated, based on more solid evidence about the management of 
periampullary cancers (i.e. distal bile duct cancer, and duodenal and ampullary 
adenocarcinomas), preoperative screening modalities, and the safety of minimally invasive 
surgery in relation to the COVID-19 pandemic.   
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TABLE 1. CHARACTERISTICS OF RESPONDENTS  
Age (years)* 49 (41-55) 
Profession, n (%) 
      Surgeon 
      Gastroenterologist  
      Oncologist 
      Surgical resident  
      Others 
 
302 (89.6) 
20 (5.9) 
4 (1.2) 
5 (1.5) 
6 (1.8) 
Type of center, n (%) 
      Academic center 
      Non-academic center 
 
286 (84.9) 
51 (15.1) 
Experience as attending specialist (years)* 18 (9-25) 
Scope of current clinical practice, n (%) 
      Hepato-pancreato-biliary surgery 
      Pancreatic surgery 
      Surgical oncology 
      General surgery 
      Gastrointestinal surgery 
      Gastroenterology 
      Medical oncology 
      Others 
 
177 (52.5) 
62 (18.4) 
32 (9.5) 
23 (6.8) 
14 (4.2) 
17 (5.0) 
5 (1.5) 
7 (2.1) 
*, median (interquartile range); n, number of respondents. 
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TABLE 2. PREOPERATIVE SCREENING FOR COVID-19  
Screening, n (%) 
      Including symptoms 
233 (87.3) 
184 (68.9) 
      Including CT chest 104 (39.0) 
      Including PCR 
      Including symptoms + CT chest + PCR 
113 (42.3) 
55 (20.6) 
No screening, n (%) 31 (11.6) 
Missing data, n (%) 3 (1.1) 
n, number of centers; PCR, polymerase chain reaction; CT, computer tomography.  
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TABLE 3. Statement outcomes – Consensus 
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TABLE 4. Statement outcomes – Moderate agreement  
 
TABLE 5. Statement outcomes – Low agreement  
 
 
 
 
 
